Home » Stocks » VCEL

Vericel Corporation (VCEL)

Stock Price: $39.01 USD 0.49 (1.27%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $39.60 +0.59 (1.51%) Jan 15, 7:55 PM
Market Cap 1.77B
Revenue (ttm) 118.34M
Net Income (ttm) 145,000
Shares Out 45.27M
EPS (ttm) 0.00
PE Ratio 13,003.33
Forward PE 76.34
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $39.01
Previous Close $38.52
Change ($) 0.49
Change (%) 1.27%
Day's Open 38.39
Day's Range 37.93 - 39.60
Day's Volume 574,564
52-Week Range 7.25 - 39.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

Record Quarterly and Full-Year Total Revenues

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...

Seeking Alpha - 1 week ago

Vericel is a high growth, disruptive biotechnology company with annual sales increasing at a 30% rate prior to the COVID-19 pandemic. The Company's tissue repair and restoration products are p...

GuruFocus - 1 week ago

The company's earnings are expected to increase exponentially in 2021

GlobeNewsWire - 4 weeks ago

CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that...

Seeking Alpha - 4 weeks ago

Vericel is a low-risk, high-quality small biotech with high growth potential. The business is already profitable with 70% gross profit margin and no debt on the balance sheet.

Seeking Alpha - 2 months ago

Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Total Net Revenues of $32.3 Million and Net Income of $3.6 Million

Zacks Investment Research - 2 months ago

Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.

Other stocks mentioned: EXAS, INMD, QQQ, XLK
Zacks Investment Research - 2 months ago

Bull of the Day: Vericel (VCEL)

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced pres...

Zacks Investment Research - 2 months ago

Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the ...

GlobeNewsWire - 3 months ago

Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual ...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently ...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced p...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced t...

GlobeNewsWire - 4 months ago

YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that th...

Other stocks mentioned: MDWD
Seeking Alpha - 5 months ago

Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Product Revenues of $20.0 Million Reported for the Second Quarter

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced th...

Zacks Investment Research - 6 months ago

Investors need to pay close attention to Vericel (VCEL) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

Second Quarter Net Product Revenues Expected to be Approximately $20 Million Second Quarter Net Product Revenues Expected to be Approximately $20 Million

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Admin...

Zacks Investment Research - 7 months ago

Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.

Other stocks mentioned: CNK, IDXX, MYGN
Seeking Alpha - 8 months ago

Vericel's (VCEL) CEO Nick Colangelo on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

Shares of Vericel (NASDAQ:VCEL) rose 2.2% after the company reported Q1 results. Quarterly Results Earnings per share fell 42.86% year over year to ($0.10), which missed the estimate of ($0.08).

Seeking Alpha - 9 months ago

Vericel Corporation: A Must-Have Biotech Post-COVID-19 Sell-Off - Behind The Idea

Seeking Alpha - 9 months ago

Vericel Is Substantially Undervalued Given Strong Balance Sheet, Profitability And Competitive Advantages

Zacks Investment Research - 10 months ago

Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.

Other stocks mentioned: AG, CWST, ENV, MYGN
Seeking Alpha - 10 months ago

Vericel Corp (VCEL) CEO Dominick Colangelo on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Vericel (VCEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 11 months ago

As of late, it has definitely been a great time to be an investor in Vericel.

Zacks Investment Research - 11 months ago

The optimism regarding small businesses remains near an all-time high albeit a slowing U.S. economy.

Other stocks mentioned: ESTE, HZO, MCB, RAD
Zacks Investment Research - 11 months ago

U.S. stocks are heavily exposed to the domestic economy where data continues to improve. And even if skeptics worry about the virus outbreak, developed markets are more stable than emerging ma...

Other stocks mentioned: ARAY, MX, RAD, RGCO
GlobeNewsWire - 1 year ago

YAVNE, Israel and CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that th...

Zacks Investment Research - 1 year ago

Vericel has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 1 year ago

Surprise Jump In Epicel Sales Highlights 'Outstanding' 3Q For Vericel

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced th...

The Motley Fool - 1 year ago

Shares jumped following upbeat third-quarter results and a guidance boost.

Seeking Alpha - 1 year ago

Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Vericel Corp (NASDAQ: VCEL), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects and severe burn wounds, is investment-wort...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass. and YAVNE, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid® expande...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced t...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced t...

Seeking Alpha - 1 year ago

Vericel Corporation's (VCEL) CEO Nick Colangelo on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Vericel's newly acquired burn care product, NexoBrid, is revolutionary, creating a "new paradigm" in burn care.

Seeking Alpha - 1 year ago

Vericel Corporation (VCEL) CEO Nick Colangelo on Q1 2019 Results - Earnings Call Transcript

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 1997
CEO
Dominick Colangelo
Employees
241
Stock Exchange
NASDAQ
Ticker Symbol
VCEL
Full Company Profile

Financial Performance

In 2019, Vericel's revenue was $117.85 million, an increase of 29.71% compared to the previous year's $90.86 million. Losses were -$9.67 million, 18.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Vericel stock is "Strong Buy." The 12-month stock price forecast is 36.21, which is a decrease of -7.18% from the latest price.

Price Target
$36.21
(-7.18% downside)
Analyst Consensus: Strong Buy